Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes Four RNAi-Related Patent Applications: Nov 16, 2006

Premium
Title: Novel RNA Polymerase III Promoter, Process for Producing the Same, and Method of Using the Same
 
Number: 20060253911
 
Filed: Feb. 16, 2004 PCT Filed: Feb. 16, 2004
 
Lead Inventor: Hiroyuki Ueno, Japan Tobacco
 
The invention, the patent application’s abstract states, “provides an RNA polymerase III promoter characterized in that a part of its sequence is substituted with a sequence capable of undergoing specific DNA recombination by Cre recombinase in such a manner functions [that] PSE and a TATA box are not impaired. This RNA polymerase III promoter can be used in a RNAi induction method with the condition that RNAi molecules to be used in analyzing gene function can be induced at an arbitrary point of time or only in a specific tissue.”
 

 
Title: Oligomeric Compounds and Compositions for Use in Modulation of Pri-miRNAs
 
Number: 20060252722
 
Filed: Jan. 10, 2006
 
Lead Inventor: Bridget Lollo, Isis Pharmaceuticals
 
According to its abstract, the patent application covers “compounds, compositions, and methods … for modulating the levels expression, processing, and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing, or function of polycistronic pri-miRNAs. The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs. Further provided are methods for selectively modulating pri-miRNA levels in a cell,” the abstract states. “Also provided [by the application] are methods for identifying oligomeric compounds that result in increased pri-miRNA levels when contacted with a cell.”
 

 
Title: Retroviral Vectors for Delivery of Interfering RNA
 
Number: 20060252153
 
Filed: Oct. 21, 2004 PCT Filed: Oct. 21, 2004
 
Lead Inventor: Dorre Grueneberg, Aventis Pharmaceuticals
 
According to the patent application’s abstract, the invention comprises “retroviral vectors for delivering interfering RNA into cells.”
 

 
Title: Methods of Identifying Aberrant RNA or RNA Targeted for Cleavage by miRNA or siRNA
 
Number: 20060252072
 
Filed: March 31, 2006
 
Lead Inventor: Pamela Green, Delaware Biotechnology Institute of the University of Delaware
 
“The invention provides novel methods of identifying RNA that is targeted for cleavage by mRNA or siRNA or genes that give rise to aberrant RNA,” the patent application’s abstract states. “The invention also provides the use in processes for identifying aberrant RNA or RNA targeted for cleavage by mRNA or siRNA of mutant eukaryotic cells or non-human organisms in which the gene encoding the enzyme AtXRN4 or its homologue is defective.”

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.